Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2008-09-16
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S305000, C544S133000, C544S137000, C544S112000, C544S183000
Reexamination Certificate
active
07425561
ABSTRACT:
The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
REFERENCES:
patent: 4203990 (1980-05-01), Yen
patent: 4970315 (1990-11-01), Schmidhalter
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5217975 (1993-06-01), Wadsworth et al.
patent: 5219849 (1993-06-01), Lotti et al.
patent: 5276043 (1994-01-01), Lippiello et al.
patent: 5346906 (1994-09-01), Baker et al.
patent: 5510355 (1996-04-01), Bencherif et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616707 (1997-04-01), Crooks et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5811442 (1998-09-01), Bencherif et al.
patent: 5824692 (1998-10-01), Lippiello et al.
patent: 5852041 (1998-12-01), Cosford et al.
patent: 5859004 (1999-01-01), Olesen
patent: 5861423 (1999-01-01), Caldwell et al.
patent: 5952339 (1999-09-01), Bencherif et al.
patent: 6953855 (2005-10-01), Mazurov et al.
patent: 173570 (1996-04-01), None
patent: WO 91/12254 (1991-08-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 95/03306 (1995-02-01), None
patent: WO 96/12711 (1996-05-01), None
patent: WO 97/01556 (1997-01-01), None
patent: WO 97/11072 (1997-03-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 98/54181 (1998-12-01), None
patent: WO 99/00385 (1999-01-01), None
patent: WO 99/51602 (1999-10-01), None
patent: WO 00/34276 (2000-06-01), None
patent: WO 01/85727 (2001-11-01), None
Evans et al., Isotopic labeling with carbon-14 and tritium, Principles of Radiopharmacology, 1992, p. 11-13.
Van Dijk, Jeanette P.M. et al., “Nicotine inhibits cytokine synthesis by mouse colonic mucosa.”European Journal of Pharmacology, 278, R11-R12 (1995).
Hanisch, Uwe-Karsten et al., “Modulation of Hippocampal Acetylcholine Release: A Potent Central Action of Interleukin-2,”The Journal of Neuroscience, vol. 13(8), pp. 3368-3374 (1993).
Madretsma, Stanley et al., “In-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells,”European Journal of Gastroenterology&Hepatology, vol. 8, No. 10, pp. 1017-1020 (1996).
Madretsma, G.S., et al. “Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-α by human mononuclear cells,”Immunopharmacology, 35 pp. 47-51(1996).
Peacock, Mark E., et al., “The Effect of Nicotine on Reproduction and Attachment of Human Gingival Fibroblasts In Vitro,”J. Periodontal, vol. 64, No. 7, pp. 658-665 (1993).
Sandborn, W.J. et al., “Nicotine tartrate liquid enemas for midly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study,”Ailment Pharmacol. Ther., 11, pp. 663-671 (1997).
Zijlstra, F. J. et al., “Effect of nicotine on rectal mucus and mucosal eicosanoids,”Gut, 35, pp. 247-251 (1994).
Pullan, Rupert D., “Colonic mucus, smoking and ulcerative colitis,”Ann R. Coll. Surg Engl., 78, pp. 85-91 (1996).
Pullan, Robert D. et al., “Transdermal Nicotine for Active Ulcerative Colitis,”The New England Journal of Medicine, vol. 330, No. 12, pp. 811-815 (1994).
Silverstein, Marc D., M.D. et al., “Cigarette Smoking and Ulcerative Colitis: A Case-Control Study,” Mayo Clinic Proc., vol. 69 pp. 425-429 (1994).
Birtwistle, Jon,Postgrad Med. J., “The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis,” vol. 72, pp. 714-718 (1996).
Ebadi, M. et al., “Neurotrophins And Their Receptors in Nerve Injury and Repair,”Neurochem Int., vol. 30, Nos. 4/5, pp. 347-374 (1997).
Matthys, Patrick, Ph.D., et al., “Cytokines and Cachexia,”Nutrition, vol. 13, No. 9, pp. 763-770 (1997).
Jonakait, G. Miller, TINS, “Neural-immune interactions in sympathetic ganglia,” vol. 16, No. 10, pp. 419-423 (1993).
Wallace, John L., et al., “Inflammatory Mediators in Gastrointestinal Defense and Injury,”Proc. Soc. Exp. Biol. Med., vol. 214, pp. 192-203 (1997).
Barnes, Peter J., Int. “Nuclear Factor-kB1”J. Biochem. Cell Biol., vol. 29, No. 6, pp. 867-870 (1997).
Sartor, R. Balfour M.D., “Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases,”The American Journal of Gastroenterology, vol. 92, No. 12, pp. 5S-11S (1997).
CAS Printout for In 173570, Apr. 1996.
CAS Printout for Schmidhalter et al., Nov. 1990.
CAS Printout for Beguc et al., Dec. 1969.
Holladay, M. W. et al.J. Med. Chem., vol. 40, No. 26, pp. 4169-4194 (1997).
Olesen, P.H. et al.,Bioorganic&Medicinal Chemistry Letters, vol. 7, No. 15, pp. 1963-1968 (1997).
Yanina et al.,Khim.-Karm, vol. 21(7), pp. 808-811 (1987).
International Search Report, PCT/US99/19906, Jan. 13, 2000.
Heeschen, Christoper, et al., “A Novel Angiogenic Pathway Mediated by Non-Neuronal Nicotinic Acetylcholine Receptors,”The Journal of Clinical Investigation, vol. 110, No. 4, pp. 527-536 (Aug. 2002).
Tracey, Kevin J., “The Inflammatory Reflex,”Nature, vol. 420, pp. 853-859 (Dec. 2002).
Wang, Hong, et al, “Nicotinic Acetylcholine Receptor α7 subunit is an Essential Regulator of Inflammation,”Nature, advance online publication, Dec. 22, 2002, pp. 1-4 (Dec. 2002).
International Search Report (PCT/US2004/005044, dated Nov. 3, 2004).
Klucik Jozef
Mazurov Anatoly A.
Miao Lan
Miller Craig Harrison
Phillips Teresa Youngpeter
Targacept, Inc.
Ward Paul V.
Wilson James O.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3990804